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Abstract: Staphylococcus coagulans is among the three most frequent pathogens of canine pyoderma.
Yet, studies on this species are scarce. Twenty-seven S. coagulans and one S. schleiferi, corresponding
to all pyoderma-related isolations from these two species at two veterinary laboratories in Lisbon,
Portugal, between 1999 and 2018 (Lab 1) or 2018 (Lab 2), were analyzed. Isolates were identified by the
analysis of the nuc gene and urease production. Antibiotic susceptibility towards 27 antibiotics was
evaluated by disk diffusion. Fourteen antibiotic resistance genes were screened by PCR. Isolates were
typed by SmaI-PFGE. Two S. coagulans isolates (2/27, 7.4%) were methicillin-resistant (MRSC, mecA+)
and four (4/27, 14.8%) displayed a multidrug-resistant (MDR) phenotype. We observed resistance
to penicillin (17/27, 63.0%), fluoroquinolones (11/27, 40.7%), erythromycin and clindamycin (3/27,
11.1%), fusidic acid (3/27, 11.1%) and tetracycline (1/27, 3.7%). The blaZ and erm(B) genes were
carried by 16 and 1 isolates resistant to penicillin and erythromycin/clindamycin, respectively. Only
three S. coagulans carried plasmids. The single S. schleiferi isolate presented an MDR phenotype.
SmaI-PFGE revealed a limited genetic diversity of S. coagulans, with a predominant lineage present
from 2001 to 2018. This study describes the first MRSC causing canine infection in Portugal and
reveals a high burden of antimicrobial resistance, with the emergence of MDR phenotypes within the
main lineages.
Keywords: Staphylococcus coagulans; Staphylococcus schleiferi; skin infections; dogs; antibiotic resis-
tance; methicillin resistance; wild-type populations; genetic lineages; plasmids
1. Introduction
Pyoderma is a common skin infection in dogs and the main cause for antimicrobial
use in small animal veterinary medicine [1]. Coagulase-positive staphylococci are the main
pathogenic agents of canine pyoderma; Staphylococcus pseudintermedius accounts for up to
90% of pyoderma-related staphylococcal infections, followed by Staphylococcus coagulans
(previously known as Staphylococcus schleiferi subsp. coagulans) and Staphylococcus aureus [1–3].
Coagulase-negative staphylococci, like Staphylococcus epidermidis, are rare agents of canine
pyoderma, frequently in association with S. pseudintermedius [1].
The species S. schleiferi was first described in 1988 by Freney and colleagues in human
clinical isolates [4], and later reported as a member of the human axilla microflora [5,6]. In
1990, Igimi and colleagues identified several isolates of S. schleiferi from dogs with otitis
externa that presented distinct characteristics from the S. schleiferi isolated from humans,
leading to the proposal of a new subspecies denominated S. schleiferi subsp. coagulans [7].
S. schleiferi subsp. coagulans differed from S. schleiferi subsp. schleiferi, among other traits, by
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the production of the enzymes coagulase and urease [7]. In 2020, a phylogenomic analysis
of the Staphylococcus genus led to the re-classification of S. schleiferi subsp. coagulans as the
new species S. coagulans and of S. schleiferi subsp. schleiferi as S. schleiferi [8].
S. coagulans is part of the dog skin microflora; it has been isolated from the skin [9] and
ear canal of healthy dogs [10], although its presence may be registered in low numbers [11].
This species has also been isolated from the skin of healthy cats [12] and, more recently,
from mouth samples of healthy seals [13]. S. coagulans is an opportunistic pathogen. The
first case of skin infection caused by S. coagulans was reported by Bes and colleagues in
2002 [14]. Since then, this species has been associated with skin, ear or urinary infections in
dogs, many of which are recurrent [10,15–19]. Albeit rare, there have been reports of human
opportunistic infections caused by S. coagulans [20–24], some of which are potentially linked
to cases of dog-to-human transmission of S. coagulans strains [22–24].
Antimicrobial resistance is a frequent trait of staphylococci and increasing rates of
antimicrobial resistance have been documented in major animal staphylococcal pathogens,
such as S. pseudintermedius and S. aureus [25]. For S. coagulans, there are a limited number
of reports on the rate of antimicrobial resistance worldwide. The first methicillin-resistant
S. coagulans (MRSC) isolates were identified in the US in 2003 [15]. These MRSC isolates,
resistant to all beta-lactam antibiotics except fifth-generation cephalosporins, were linked
to recurrent cases of canine pyoderma [15]. Since then, several US-based studies have
indicated frequency rates of MRSC from 0% [26] up to 75%, mainly associated with cases
of recurrent skin or ear infections in dogs, many of which subjected to previous antibi-
otic therapy [15,27–33]. In fact, previous treatment with penicillin or a cephalosporin
has been reported as a risk factor for the emergence of MRSC [34]. Studies conducted
from other geographic regions have also shown a variability in frequency rates of MRSC
isolates linked to skin, ear or urinary infections, from 0% in Slovenia [35], the UK [16],
Scotland [36], Italy [37] Portugal [38], Australia [39] and Japan [10] to rates of 12.5–20%
in Brazil [17,40], 24% in Korea [41], ca. 30% in Japan [18,42] and 70% in Thailand [43].
However, the MRSC frequency rates determined for some of these studies may not be pre-
cise, due to the low number of isolates studied, lack of differentiation between S. schleiferi
subspecies and, most importantly, absence of clinical breakpoints for the detection of
methicillin resistance in these species, which were only recommended by CLSI from 2018
onwards [44]. Resistance to other antibiotic classes has also been reported, associated or not
to methicillin-resistance, and usually includes resistance to fluoroquinolones [37,45], peni-
cillin, erythromycin, clindamycin, gentamicin, chloramphenicol, tetracycline and fusidic
acid [10,18,19,29,30,32,34,39,43]. Despite the low prevalence of S. coagulans, and conse-
quently, of the absolute numbers of strains analyzed, an increasing trend of antimicrobial
resistance has been reported for this species [33,46], which may affect the management of
infections caused by S. coagulans.
In a previous study conducted in Portugal, S. coagulans and S. schleiferi were associated
with over 11% of skin, ear and urinary infections in pets during a 16-year period (1999–2014)
in a veterinary research laboratory receiving samples from a veterinary teaching hospital
and private practices in Lisbon area [38]. Although no MRSC isolates were detected in
that earlier study, an increasing trend of antimicrobial resistance burden was observed for
S. coagulans during the 16-year timeframe [38]. In the present work, we expand that previ-
ous study, focusing on all the S. coagulans and S. schleiferi associated with skin infections,
isolated from 1999 to 2018, as well as all S. coagulans and S. schleiferi related to skin infections
and collected during 2018 at a second private veterinary diagnostic laboratory. The aims
of our study were to analyze the antimicrobial resistance burden of these pathogens and
their association with genotypic determinants of resistance, plasmid content and molecular
lineages; the latter two traits have not been studied yet in Portugal and have been rarely
documented worldwide.
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2. Results
2.1. Identification of S. coagulans and S. schleiferi Isolates
The identification of S. coagulans and S. schleiferi isolates among an initial collection of
89 pyoderma-related Staphylococcus isolates was performed or confirmed by the species-
specific nuc-PCR strategy proposed by Sasaki and colleagues [47], followed by detection
of urease activity [44]. Of the 89 isolates screened, 28 were identified as S. coagulans
or S. schleiferi by the nuc-PCR. Of these, 27 were urease-positive and thus identified as
S. coagulans, whereas one isolate was urease-negative and identified as S. schleiferi. All
isolates were collected from dogs and linked to pyoderma; two S. coagulans isolates were
collected from the same dog, corresponding to skin swabs sampled one year apart. In
sum, the study collection comprised 27 S. coagulans isolates; 21 collected over 19 years in a
veterinary research lab (Lab 1), 7 collected during 2018 at a veterinary diagnostic lab (Lab 2)
and a single S. schleiferi isolate collected at Lab 1 in 2016.
2.2. Antimicrobial Resistance Profiles and Association with Resistance Determinants
The antibiotic susceptibility profiles of all S. coagulans isolates are discriminated in
Table 1 and Figure 1. Inhibition zone diameters for all antibiotics studied are shown in
Tables S1–S3 of the Supplementary Materials.
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Antibiotic susceptibility testing showed that of the 27 isolates in study, 16 (16/27,
59.3%) were resistant to one or two antibiotics of distinct classes and 4 (4/27, 14.8%)
displayed a multidrug resistance phenotype, showing resistance to, at least, three different
classes of antibiotics. Only seven (7/27, 25.9%) were susceptible to all antibiotics tested.
Two S. coagulans isolates (2/27, 7.4%) were resistant to oxacillin and carried the mecA gene,
being classified as MRSC, and thus, resistant to all beta-lactams, except for fifth-generation
cephalosporins. The mecA gene was not detected in the remaining isolates.
The most common resistance pattern for S. coagulans was monoresistance to penicillin,
observed in six isolates (6/27, 22.2%), followed by resistance to penicillin and fluoro-
quinolones (5/27, 18.5%). The MDR isolates were characterized by resistance to penicillin,
fluoroquinolones and fusidic acid (1 out of 4 isolates), or penicillin, erythromycin and clin-
damycin (2 out of 4 isolates), and additional resistance to fluoroquinolones and tetracycline
(1 out of 4 isolates). The two MRSC isolates also showed resistance to fluoroquinolones.
Resistance to penicillin was the most frequently observed phenotype, detected in 17 S.
coagulans (17/27, 63.0%). Of these, one isolate presented a zone inhibition diameter (ZD) of
31 mm but showed a sharp inhibition border, being considered a beta-lactamase producer
and penicillin-resistant. Another isolate showed an ZD of 33 mm and a fuzzy border but
carried the mecA, and thus, was also considered resistant to penicillin [48]. The blaZ gene
encoding the beta-lactamase BlaZ was present in 16 of the 17 penicillin-resistant isolates.
Table 1. Antibiotic susceptibility profiles and antibiotic resistance genes detected for the 27 canine pyoderma associated
S. coagulans isolates studied. Data are only presented for antibiotics with established breakpoints.
Antibiotic
ZD Breakpoint Number of Isolates (%) Resistance Determinants
(No. Isolates)S (mm) R (mm) S I R
Penicillin ** ≥29 a ≤28 a 10 (37.0%) - 17 (63.0%) blaZ (16) and/or mecA (2)
Oxacillin ** ≥18 ≤17 25 (92.6%) - 2 (7.4%) mecA (2)
Enrofloxacin * ≥23 ≤16 16 (59.3%) 2 (7.4%) 9 (33.3%) QRDR mutations: GrlA
[S80I, S80R, S80G]; GyrA
[S80F, S80Y, E88A, E88G]
Ciprofloxacin ** ≥21 ≤15 17 (63.0%) 4 (14.8%) 6 (22.2%)
Moxifloxacin ** ≥24 ≤20 21 (77.8%) 2 (7.4%) 4 (14.8%)
Erythromycin ** ≥23 ≤13 24 (88.9%) 2 (7.4%) 1 (3.7%) erm(B) (1)
Clindamycin * ≥21 ≤14 24 (88.9%) 0 (0%) 3 (11.1%) erm(B) (1)
Quinupristin-dalfopristin *** ≥21 <18 27 (100%) 0 (0%) 0 (0%) -
Tetracycline * ≥23 ≤17 26 (96.3%) 0 (0%) 1 (3.7%) -
Minocycline ** ≥19 ≤14 27 (100%) 0 (0%) 0 (0%) -
Tigecycline *** ≥19 <19 27 (100%) 0 (0%) 0 (0%)
Fusidic acid *** ≥24 <24 25 (92.6%) - 2 (7.4%) -
Linezolid ** ≥21 ≤20 27 (100%) - 0 (0%) -
Chloramphenicol ** ≥18 ≤12 27 (100%) 0 (0%) 0 (0%) -
Trimethoprim-sulfamethoxazole ** ≥16 ≤10 27 (100%) 0 (0%) 0 (0%) -
Rifampicin ** ≥20 ≤16 27 (100%) 0 (0%) 0 (0%) -
Gentamicin ** ≥15 ≤12 27 (100%) 0 (0%) 0 (0%) -
Amikacin *** ≥18 <18 27 (100%) - 0 (0%) -
Tobramycin *** ≥18 <18 27 (100%) - 0 (0%) -
Kanamycin *** ≥18 <18 27 (100%) - 0 (0%) -
ZD: zone inhibition diameter; S: susceptible; I: intermediate; R: resistant; * Breakpoint established by CLSI for staphylococci isolated from
animals, document VET01S ED5 [48]; ** Breakpoint established by CLSI for staphylococci isolated from humans, document M100-S30 [49];
*** Breakpoint established by EUCAST [50]; a Isolates with a ZD towards penicillin > 29 mm, but with a sharp inhibition border were
considered producers of beta-lactamase and thus resistant to penicillin [48].
Resistance to fluoroquinolones was observed in 11 out of the 27 S. coagulans isolates
(11/27, 40.7%). These 11 isolates were resistant (n = 9) or intermediate (n = 2) to enrofloxacin;
10 (37.0%) were resistant (n = 6) or intermediate (n = 4) to ciprofloxacin; and 6 (22.2%) were
resistant (n = 4) or intermediate (n = 2) to moxifloxacin. Sequencing the quinolone-resistance
determining region (QRDR) of the grlA and gyrA genes of the 11 isolates presenting flu-
oroquinolone resistance revealed six distinct patterns of mutations in GrlA and GyrA
(Figure 1). The pair GrlA: S80I/GyrA:S80F, observed in four isolates, was the only as-
sociated with a resistance phenotype to the three fluoroquinolones tested. On the other
hand, the single GrlA mutation S80R was present in one isolate with intermediate pheno-
type only towards enrofloxacin. The remaining mutation patterns GrlA:S80I/GyrA:E88A,
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GrlA:S80R/GyrA:S80F, GlA:S80R/GyrA:E88G and GrlA:S80G/GyrA:S80Y were all linked
to resistance or intermediate to either ciprofloxacin or enrofloxacin.
Resistance to erythromycin was detected in three S. coagulans isolates (3/27, 11.1%),
two of which were intermediate. These three isolates showed also constitutive resistance
to clindamycin (3/27, 11.1%). From the seven macrolide-lincosamide resistance genes
screened, only erm(B) was detected in the single isolate classified as resistant to both
erythromycin and clindamycin. No resistance gene was detected for the remaining two
isolates resistant to clindamycin and intermediate to erythromycin.
Resistance to fusidic acid was detected in two S. coagulans isolates (2/27, 7.4%) and to
tetracycline in a single isolate (1/27, 3.7%), but none of these isolates harbored any of the
resistance determinants screened, fusB/fusC or tetK/tetM/tetL, respectively.
The single S. schleiferi isolate of this collection presented an MDR phenotype, with
resistance to penicillin, fluoroquinolones and fusidic acid, and harbored the blaZ gene and
the QRDR mutations GrlA:S80R and GyrA:S80F. Neither of the fusidic acid resistance genes
screened, fusB/fusC, were detected in this isolate.
None of the S. coagulans or S. schleiferi isolates were resistant to chloramphenicol,
quinupristin-dalfopristin, trimethoprim-sulfamethoxazole, linezolid, rifampicin, minocy-
cline, tigecycline nor to the aminoglycosides gentamicin, tobramycin, kanamycin or amikacin.
2.3. Distributions of Zone Inhibition Diameters for Antibiotics with No Breakpoints Established
One of the aims of this study was to evaluate the overall burden of antimicrobial
resistance in S. coagulans to a wide set of antibiotics for multiple classes, independently
of their recommended use for canine skin infections [1,2]. This evaluation is impaired
by the limited number of breakpoints recommended for S. coagulans/S. schleiferi by Clini-
cal Laboratory and Standards Institute (CLSI) or European Committee on Antimicrobial
Susceptibility Testing (EUCAST). For most antibiotics, the recommendation is to use break-
points established for Staphylococcus spp. isolated from humans [48] and/or established for
S. aureus [50]. To overcome this limitation, we estimated the ZD-based cut-off value (COWT)
of S. coagulans for antibiotics with no breakpoints available. This parameter corresponds to
the smallest ZD value of the wild-type population (the population without phenotypically
expressed resistance mechanisms) [51]. It also allows the detection of putative non-wild
type populations (with phenotypically expressed resistance mechanisms) in a given bac-
terial collection. Thus, the distributions of zone inhibition diameters were analyzed to
evaluate the possible presence of resistance determinants in S. coagulans for the antibiotics
mupirocin, florfenicol, neomycin, bacitracin, novobiocin and apramycin (Figure 2). This
analysis only took into consideration the 27 isolates identified as S. coagulans.
The Normalized Resistance Interpretation (NRI) method was used to estimate the
distribution of the putative wild-type (WT) population and calculate the COWT value for
this population. All zone diameter distributions were unimodal. The normalized distri-
butions of the WT populations were validated as they all included over 15 observations
and each associated standard deviation (SD) was below the acceptable SD upper limit of
3.38 mm (Table 2). The application of the estimated COWT values showed the absence
of NWT populations of S. coagulans towards all the six antibiotics tested, indicating the
absence of isolates with resistance mechanisms to these antibiotics in our collection.
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Apramycin 18 2.11 ≥18 <18
Bacitracin 13 1.85 ≥13 <13
Florfenicol 22 2.64 ≥22 <22
Mupirocin 32 3.21 ≥32 <32
Neomycin 18 2.20 ≥18 <18
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2.4. Plasmid Profiling and Association with Antibiotic Resistance
Plasmid DNA was isolated for all isolates. From the 27 S. coagulans studied, only 3
(3/27, 11.1%) carried plasmids. Two isolates showed a single plasmid of ≥23 kb, whereas
the remaining S. coagulans presented a single plasmid of ≤3 kb. Of the two isolates
harboring a large plasmid, one showed resistance to penicillin and carried the blaZ gene,
while the other was only resistant to fusidic acid with no associated resistance determinant
detected. The isolate harboring the small plasmid showed resistance to penicillin and the
blaZ gene as well as an intermediate phenotype towards enrofloxacin.
2.5. Molecular Typing and Association with Antimicrobial Resistance Phenotypes
All isolates, but one, were subjected to molecular typing by SmaI-PFGE (Figure 1). The
collection comprised nine pulsed-field gel electrophoresis (PFGE) types, classified A to I,
and thirteen subtypes. The PFGE type A was the most common, represented by over half
of the S. coagulans isolates (14/27, 51.8%) and comprising eight subtypes. PFGE types F
and G each included three isolates (3/27, 11.1%) and comprised three and two subtypes,
respectively. The remaining six PFGE types were represented by a single isolate. The single
S. schleiferi isolate presented a PFGE pattern indistinguishable from S. coagulans, sharing
the PFGE type A1 together with two S. coagulans isolates. The two S. coagulans isolates
collected one year apart from the same dog belonged to different subtypes of PFGE type
F. A calculation of the Simpson’s Index of Diversity (SID) based on the S. coagulans PFGE
types revealed that this collection is not very diverse (SID = 0.70, CI: 0.51–0.89).
The main PFGE type A was present in isolates collected from 2001 to 2018. All iso-
lates with this PFGE pattern showed resistance to at least one antibiotic. Additionally, all
four MDR isolates belonged to PFGE type A. The two MRSC isolates belonged to two
distinct and unique PFGE types (D and E). We observed an increase in antimicrobial re-
sistance accompanying the year of isolation of the S. coagulans isolates, detectable within
the main PFGE types. For example, up to 2014, isolates from PFGE type A (n = 7) pre-
sented monoresistance to penicillin (n = 3) with additional resistance to fluoroquinolones
(n = 2) or macrolides-lincosamides (n = 2, MDR). However, from 2015 to 2018, the remain-
ing isolates with PFGE type A (n = 7) presented more diverse and additional resistance
phenotypes, namely resistance to penicillin-fluoroquinolones-fusidic acid (n = 1, MDR)
or resistance to penicillin-fluoroquinolones-macrolides-lincosamides-tetracycline (n = 1,
MDR), besides the patterns previously detected (monoresistance to penicillin, n = 2 or
resistance to penicillin-fluoroquinolones, n = 3). Within PFGE type F, the emergence of
resistance to fluoroquinolones was detectable in the two isolates collected in 2015/2016,
whereas for PFGE type G, resistance to fusidic acid was detected in the 2018 isolate.
The increasing antimicrobial resistance was also illustrated by the detection of the two
MRSC isolates in 2018, belonging to PFGE types D and E.
3. Discussion
Despite being a relevant agent of canine pyoderma, S. coagulans is still poorly char-
acterized regarding antimicrobial resistance traits and, particularly, its circulating clonal
lineages. A previous study in Portugal surveyed the antimicrobial resistance burden of
S. coagulans associated with several types of infection during a 16-year period (1999–2014).
During that timeframe, no MRSC isolates were detected, but MDR phenotypes were ob-
served [38]. In this work, we expanded the collection to encompass the years 2015 up to
2018; additionally, we included all isolates collected during 2018 at a second veterinary
diagnostic laboratory. We also broadened the analysis to plasmid profiling and molecular
typing. However, we focused our study on isolates related to skin infections.
This study revealed that a significant proportion of all the non-S. pseudintermedius or
non-S. aureus isolates collected from companion animals skin infections during the time
period studied was identified as S. coagulans (27/89, 30.3%), while a single isolate (1/89,
1.1%) corresponded to S. schleiferi. The low total number of S. coagulans or S. schleiferi
isolates collected during this 19-year period (1999–2018) reflects the lower rate of canine
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skin infections caused by these pathogens when compared to S. pseudintermedius [3]. Several
studies have shown that S. coagulans is commonly the second most isolated staphylococci
isolated from skin samples of canine pyoderma, in frequencies varying from 3% [32,52] to
up to 10% [18]. The predominance of S. coagulans over S. schleiferi in canine skin samples
observed in our study agrees with other studies [31,32], although some works documented
similar or higher frequency of S. schleiferi in canine pyoderma [53,54].
We registered a high rate of antimicrobial resistance in the collection studied. In total,
75% of the isolates (21/28, considering S. coagulans and S. schleiferi) were resistant to at
least one antibiotic and 17.9% (5/28) were MDR. This study also reports the first MRSC
isolates in dogs in Portugal. A comparison of the antimicrobial resistance in the S. coagulans
isolated between the 1999–2014 period (13 isolates obtained during the study by Couto
and colleagues [38]) with the isolates collected afterward (2015–2018, n = 14) revealed an
increase in the antimicrobial-resistant isolates. This was manifested by the decrease in the
total number of fully-susceptible isolates (n = 5 in 1999–2014 to n = 2 in 2015–2018) and
the increase in total number of isolates resistant to one or two classes of antibiotics (n = 6
in 1999–2014 to n = 10 in 2015–2018). Most importantly, we reported the emergence of
two MRSC isolates from distinct lineages (different PFGE types) in the last year surveyed
(2018). We also describe the emergence, since 2016, of resistance to fusidic acid, which is
widely used in the topical treatment of human and canine skin infection caused by either S.
coagulans or S. schleiferi. Worryingly, this increase in antimicrobial resistance in S. coagulans
has also been reported in other countries, namely in the US [32,33,55]. The frequency rates
of MRSC and MDR detected in our study are higher than the ones previously reported for
other European countries [16,35–37], although there is a lack of recent surveys for direct
comparison purposes.
The two MRSC isolates described in this study were also resistant to fluoroquinolones,
as observed in other studies [30]. Nearly half of the S. coagulans studied were resistant
to fluoroquinolones, and all carried QRDR mutations in a diverse range of combina-
tions. High levels of resistance to fluoroquinolones have been reported worldwide in
S. coagulans collected from dogs, irrespective of methicillin-resistance status, including
in the UK [16], Italy [37], Japan [18] and the US [19]. The description of QRDR muta-
tions in S. coagulans is sparce. A study by Intorre and colleagues identified the mutations
GrlA: S80R or GyrA: E88G in S. coagulans resistant to old generation fluoroquinolones
(enrofloxacin, ciprofloxacin and orbifloxacin) yet susceptible to moxifloxacin, gatifloxacin
and trovafloxacin [45]. In the present study, we identified a wider set of QRDR muta-
tions. Among the six different patterns of mutations identified, only the combination
GrlA:S80I and GyrA:S80F was linked to resistance to the three fluoroquinolones tested,
whereas a single mutation in GrlA (S80R) was associated with an intermediate phenotype
towards enrofloxacin.
In the last decades, a decrease has been observed in the susceptibility to penicillin,
erythromycin, clindamycin and to a lesser extent gentamicin or other aminoglycosides
and tetracycline in S. coagulans, but the resistance determinants associated with these
resistance phenotypes is scarcely documented [10,18,19,36,41–43]. As observed in other
studies, resistance to penicillin was linked to the presence of the blaZ gene, encoding the
beta-lactamase BlaZ, except for one MRSC isolate which did not carry this determinant.
Contrary to other staphylococci, blaZ carriage was not associated with large multiresistance
plasmids. Resistance to macrolides and lincosamides is common in S. coagulans and has
been linked to the presence of erm(B) and/or erm(C) genes [41–43]. In our collection, only
one out of the three isolates resistant to these antibiotics harbored the erm(B). Although
negative for the other six resistance genes screened [erm(A), erm(C), msrA, mph(C), vga(A)
and vga(C)], the remaining two resistant isolates could carry other determinants, such as
additional erm genes like erm(43) or lnu(B), which are not usually linked to plasmids [56].
Resistance to fusidic acid was detected in three S. coagulans and S. schleiferi collected
from 2016 onwards, highlighting the recent emergence of resistance to this antibiotic.
However, none carried the two resistance determinants screened, fusB/fusC, which are
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usually associated with plasmids or other mobile genetic elements. Resistance to this
antibiotic could be linked to mutations occurring in the fusA gene, which are common in
other staphylococcal species [56]. Regarding resistance to tetracycline, none of the tet genes
screened was found in the single tetracycline-resistant S. coagulans detected. However, this
isolate could carry the tet(O) determinant, as observed in the study by Chanchaithong and
colleagues [43].
Despite the increase registered in antimicrobial resistance in S. coagulans in Portugal
in the last two decades, resistance phenotypes are still mainly restricted to a few antibi-
otic classes, namely beta-lactams, fluoroquinolones, macrolide-lincosamides and fusidic
acid. Reports from other countries such as Thailand [43] showed a higher diversity of
resistance phenotypes and resistance determinants in S. coagulans. The low diversity of
resistance genes encountered in our collection could be associated with the low abundance
of plasmids.
Our knowledge on the molecular epidemiology of S. coagulans is rather limited to
a few studies with a limited number of isolates. These have used SmaI-PFGE to evalu-
ate the clonality of this species, indicating a high clonality within the species and that
S. coagulans and S. schleiferi often present indistinguishable PFGE patterns [10,19,29,33,43].
Our data also show that S. coagulans collected in Portugal (Lisbon area) throughout the
last two decades present a low genetic diversity (Simpson’s index of diversity, SID = 0.70),
with a predominant lineage encompassing over half of the isolates collected through al-
most the entire time span of the collection. Nevertheless, some heterogeneity was found
within this predominant lineage, with isolates varying in resistance phenotypes and resis-
tance determinants.
We also analyzed the ZD distributions and corresponding COWT values for six antibi-
otics (apramycin, bacitracin, florfenicol, mupirocin, neomycin and novobiocin) with no
breakpoints available for S. coagulans. These antibiotics are not used or rarely recommended
(mupirocin) for the treatment of skin infections in dogs [1,2]. Nevertheless, the emergence
and dissemination of resistance to these antibiotics in several staphylococci of animal origin
is worrisome [56]. Thus, the availability of cut-off values that allow the identification
of isolates potentially harboring resistance mechanisms to these antibiotics could be a
valuable tool in future antimicrobial resistance surveillance studies in S. coagulans.
The results gathered in this study are particularly worrisome when analyzed in
conjunction with data on the classes of antibiotics most prescribed in small animal practice.
Data from the European Medicines Agency (EMA) and a report by Oliveira and colleagues
highlight that beta-lactams, fluoroquinolones, macrolides and tetracyclines represent the
majority of antibiotics prescribed for treatment of skin infections in small animals [57,58].
Although fusidic acid is not listed in these two studies, it is recommended for the topical
management of canine pyoderma [1,2] and, worryingly, is frequently used (for human or
animal use) without requiring medical prescription. Our data suggest that the high burden
of antimicrobial resistance in S. coagulans may reflect the usage of antibiotics recommended
for the treatment of canine pyoderma.
4. Materials and Methods
4.1. Bacterial Isolates
The initial collection studied (total n = 89) included all isolates previously identified as
S. schleiferi or Staphylococcus spp. (non-S. pseudintermedius and non-S. aureus) causing skin
infections in pets collected over 19 years (1999–2018) at a veterinary research laboratory
providing diagnostic services for a veterinary teaching hospital and private veterinary
clinics in the Lisbon area (Lab 1, n = 40) and at a private veterinary diagnostic clinic during
2018 (Lab 2, n = 49) (Table 3). This collection included thirteen isolates collected from 1999
to 2014 at Lab 1 and previously identified as S. schleiferi that were partially characterized
in a previous study [38]. The type strains S. coagulans DSM 6628T and S. schleiferi DSM
4807T were acquired from DSMZ GmbH (Germany) and included in the study as controls.
All isolates were grown in tryptone soya broth or agar (TSB/TSA, Thermo Scientific™
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Oxoid™, Basingstoke, UK) at 37 ◦C, at 180 rpm (for broth cultures). Bacterial stocks were
kept at −80 ◦C in TSB supplemented with 10% (v/v) glycerol.
Table 3. Brief description of the S. coagulans (n = 27) and S. schleiferi (n = 1) isolates associated with
canine skin infections.
Isolate Identification Biological Sample Year Laboratory
BIOS-V1 * S. coagulans skin swab 2015 Lab1
BIOS-V2 S. coagulans skin swab 2012 Lab1
BIOS-V3 S. coagulans skin swab 2014 Lab1
BIOS-V9 S. coagulans skin swab 2018 Lab1
BIOS-V35 S. coagulans skin swab 2018 Lab1
BIOS-V41 S. coagulans perianal skin swab 2018 Lab1
BIOS-V42 S. coagulans skin swab 2001 Lab1
BIOS-V43 S. coagulans skin swab 2004 Lab1
BIOS-V44 S. coagulans skin swab 2005 Lab1
BIOS-V45 S. coagulans perianal fistula swab 2008 Lab1
BIOS-V46 S. coagulans skin swab 1999 Lab1
BIOS-V47 S. coagulans skin swab 2003 Lab1
BIOS-V51 S. coagulans skin swab 2007 Lab1
BIOS-V91 S. coagulans axillar skin swab 2004 Lab1
BIOS-V93 S. coagulans skin swab 2007 Lab1
BIOS-V94 S. coagulans skin swab 2007 Lab1
BIOS-V95 S. coagulans skin swab 2013 Lab1
BIOS-V98 S. coagulans skin swab 2015 Lab1
BIOS-V107 S. coagulans skin swab 2015 Lab1
BIOS-V126 * S. coagulans skin swab 2016 Lab1
BIOS-V139 S. schleiferi skin swab 2016 Lab1
BIOS-V191 S. coagulans skin swab 2018 Lab2
BIOS-V205 S. coagulans skin swab 2018 Lab2
BIOS-V209 S. coagulans skin swab 2018 Lab2
BIOS-V232 S. coagulans epidermal collarette 2018 Lab2
BIOS-V243 S. coagulans skin swab 2018 Lab2
BIOS-V265 S. coagulans skin swab 2018 Lab2
BIOS-V289 S. coagulans Interdigital skin swab 2018 Lab2
* Isolates collected from the same dog.
4.2. Total DNA and Plasmid DNA Isolation
Total DNA was isolated by the boiling method [59] and used as a template for all
PCR protocols. Plasmid DNA was isolated with NZYMiniprep Kit (NZYTech, Lisbon,
Portugal), according to the manufacturer’s recommendations and with the addition of an
incubation step with lysostaphin at 35 mg/L for 60 min at 37 ◦C following resuspension
of the bacterial pellet with buffer A1. All plasmid preparations were analyzed in 1%
agarose gel electrophoresis in TAE 1X buffer at 80 V for 90 min using the molecular ladder
lambda/HindIII (Thermo Scientific™).
4.3. Identification of the Isolates
The identification of the isolates as S. coagulans or S. schleiferi was confirmed by a
species-specific nuc PCR approach described by Sasaki et al. [47], after decreasing the
annealing temperature from 56 ◦C to 50 ◦C, to obtain a good specific amplification for
the two type strains used as positive controls. Total DNA from the type or reference
strains S. pseudintermedius DSM 21284T (DSMZ GmbH), S. aureus ATCC® 259323™ and
S. epidermidis ATCC® 12228™ (LGC Standards, S.L.U, Barcelona, Spain) were included as
negative controls. The differentiation between S. coagulans and S. schleiferi was carried out,
for each isolate, by detection of urease activity after growth in Christensen urea agar at
35 ◦C for up to 48 h [44]. Conversion of the medium color from yellow to pink indicates
the presence of urease activity. The urease-negative strains S. schleiferi DSM 4807T and
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Escherichia coli ATCC® 2922™, and the urease-positive strains S. coagulans DSM 6628T and
Klebsiella pneumoniae ATCC® BAA 1706™ were included as controls.
4.4. Antibiotic Susceptibility Testing
Antibiotic susceptibility was determined by agar disk diffusion on Mueller-Hinton
agar plates (Thermo Scientific™ Oxoid™) according to CLSI recommendations for bacteria
isolated from animals [48] or EUCAST recommendations [50]. We studied a wide panel
of antibiotics, not only used in veterinary practice, but also human medicine, to evalu-
ate the overall burden of antimicrobial resistance in S. coagulans. Antibiotic disks were
acquired from Thermo Scientific™ Oxoid™ or MAST Group (pradofloxacin) (Liverpool,
UK). Susceptibility profiles were interpreted according to CLSI VET01S-ED5 recommenda-
tions for enrofloxacin (5 µg), clindamycin (2 µg) and tetracycline (30 µg) [48] or according
to CLSI M100-S30 (bacteria isolated from humans) for penicillin (10 U), oxacillin (1 µg),
ciprofloxacin (5 µg), moxifloxacin (5 µg), gentamicin (10 µg), erythromycin (15 µg), minocy-
cline (30 µg), trimethoprim/sulfamethoxazole (1.25/23.75 µg), chloramphenicol (30 µg),
linezolid (30 µg), rifampicin (5 µg) [49]; or according to EUCAST for tobramycin (10 µg),
kanamycin (30 µg), amikacin (30 µg), quinupristin-dalfopristin (15 µg), fusidic acid (10 µg)
and tigecycline (15 µg) [50]. Other antibiotics were tested for which no breakpoints are
established, namely pradofloxacin (5 µg), neomycin (30 µg), apramycin (15 µg), florfenicol
(30 µg), novobiocin (30 µg), mupirocin (200 µg) and bacitracin (10 U). Isolates categorized
as intermediate using the CLSI breakpoints were considered resistant, according to these
recommendations. The D-zone test was performed for detection of inducible clindamycin
resistance [49]. The reference strains S. aureus ATCC®25923™ and S. aureus ATCC®29213™
and the type strains S. coagulans DSM 6628T and S. schleiferi DSM 4807T were used as
quality controls. Multidrug resistance (MDR) was considered as not-susceptibility to, at
least, one agent of, at least, three classes of antimicrobials [60].
4.5. Calculation of Cut-Off (COWT) Values
The ZD-based COWT values were estimated using the Normalized Resistance Inter-
pretation (NRI) method [51,61]. This method uses the distributions of inhibition zone
diameters to make a least-square regression analysis to determine the putative wild-type
(WT) population, the mean inhibition zone diameter and the associated standard devi-
ation (SD) for each species-antimicrobial agent combination. The COWT corresponds to
the smallest inhibition zone diameter presented by the putative WT population and is
calculated at 2.5X the SD above the mean value and rounded up to the lowest absolute
value [51,61]. Thus, the COWT allows the distinction between putative WT populations
(devoid of phenotypically-detectable acquired resistance mechanisms) and non-wild-type
populations (NWT, with phenotypically-detectable acquired resistance mechanisms) [62].
The COWT estimated by the NRI method will include 99.4% of the WT population [61].
The NRI method was used with permission from the patent holder, Bioscand AB, TÄBY,
Sweden (European patent No 1383913, US Patent No. 7,465,559). The automatic and
manual excel programs were made available through courtesy by P. Smith, W. Finnegan
and G. Kronvall at http://www.bioscand.se/nri/ (accessed on 2 December 2020).
4.6. Screening of Resistance Determinants
Carriage of the beta-lactam resistance genes blaZ and mecA was screened by PCR for
all isolates, whereas the genes erm(A), erm(B), erm(C), msrA, mph(C), vga(A) and vga(C)
for resistance to macrolides and/or lincosamides, genes tet(K), tet(L), tet(M) for resistance
to tetracyclines and genes fusB and fusC for resistance to fusidic acid were only screened
by PCR for isolates a resistant or intermediate phenotype. The presence of mutations
associated with fluroquinolone resistance was screened by sequencing of the quinolone-
resistance determining region (QRDR) of the genes grlA and gyrA. Amplification products
were purified using the kit NZYGelpure (NZYTech, Lisboa, Portugal) and sequenced.
Sequences were analyzed using the programs SnapGene Viewer (GSL Biotech; available
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at snapgene.com), translated to polypeptide sequnces, aligned in MEGA v. 7.0.26 and
compared against the GrlA and GyrA sequences of the type strain S. coagulans DSM6628T
(GenBank assembly accession no. GCA_002901995.1). All primers used for the detection of
resistance genes or mutations are listed in Supplementary Table S4, while the strains used
as controls for PCR assays are discriminated in Supplementary Table S5.
4.7. Molecular Typing by SmaI-PFGE
All isolates in study were subjected to SmaI-PFGE typing. Briefly, agarose disks
containing genomic DNA were prepared and restricted with SmaI, as previously described
for S. aureus [63]. Restriction fragments were then resolved by PFGE in a contour-clamped
homogeneous electric field (CHEF) apparatus (CHEF-DRIII, Bio-Rad, Hercules, CA, USA),
using the following running parameters: 14 ◦C, 200 V (6 V/cm), 120◦, 5 s of initial switch,
40 s of final switch and 21 h of running time [19]. In each run, control agarose disks were
included containing the genomic DNA of the reference strain S. aureus NCTC8325 (used
for gel normalization) and the PFG DNA Ladder (New England Biolabs). Macrorestriction
profiles were analyzed with BioNumerics software version 7.6 (Applied Maths, Kortrijk,
Belgium) using the unweighted pair group method using arithmetic averages and the Dice
similarities coefficient. Band position tolerance and optimization were set at 1% and 0.5%,
respectively. Isolates with a similarity coefficient ≥ 81% were considered as belonging to
the same PFGE type, whereas isolates with a similarity coefficient ≥ 97% were considered
as belonging to the same PFGE sub-type [64]. The genetic diversity of the collection was
calculated, based on PFGE types, by Simpson’s index of diversity with a confidence interval
of 95% [65].
5. Conclusions
This study on S. coagulans associated with canine pyoderma highlights a high burden
of antimicrobial resistance in S. coagulans in Portugal during the last two decades, including
the emergence of MRSC. This work also reveals a low genetic diversity and a low content
of plasmids in the circulating S. coagulans. Yet, new lineages with relevant resistance phe-
notypes were identified. This scenario may have a high impact on the future management
of canine pyoderma caused by S. coagulans.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/antibiotics10050518/s1, Table S1: Distribution of inhibition zone diameters of 21 antibiotics for
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no breakpoint or epidemiological cut-off value for the 27 S. coagulans studied; Table S3: Inhibition
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this study; Table S5: Control strains used in the screening of antibiotic resistance genes.
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